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Abstract
Purpose: Research on genomic medicine integration has focused on applications at the 
individual level, with less attention paid to implementation within clinical settings. Therefore, we 
conducted a qualitative study using the Consolidated Framework for Implementation Research 
(CFIR) to identify system-level factors that played a role in implementation of genomic medicine 
within Implementing GeNomics In PracTicE (IGNITE) Network projects.
Methods: Up to four study personnel, including principal investigators and study coordinators 
from each of six IGNITE projects were interviewed using a semi-structured interview guide that 
asked interviewees to describe study site(s), progress at each site, and factors facilitating or 
impeding project implementation. Interviews were coded following CFIR inner-setting constructs.
Results: Key barriers included: (1) limitations in integrating genomic data and clinical decision 
support tools into electronic health records; (2) physician reluctance towards genomic research 
participation and clinical implementation due to a limited evidence base; (3) inadequate 
reimbursement for genomic medicine; (4) communication among and between investigators and 
clinicians; (5) lack of clinical and leadership engagement.
Conclusion: Implementation of genomic medicine is hindered by several system-level barriers 
to both research and practice. Addressing these barriers may serve as important facilitators for 
studying and implementing genomics in practice.
Keywords
Implementation; Qualitative; Genomics; Electronic Health Record; Clinical Engagement
Introduction
Dramatic advances in genomic discoveries and science have led to repeated predictions that 
genomic medicine will revolutionize health care delivery.1-3 The potential clinical 
applications of genomic advances are vast and include improved assessment of disease risk, 
personalized targeted therapies and risk reduction strategies, and the potential for avoiding 
adverse drug reactions.4-6 Several specific applications of genomic advances are being 
incorporated successfully into clincal care in some settings, including the use of tumor 
sequencing for selection of treatment based on the molecular characterization of the tumor, 
the use of genome or exome sequencing for the diagnosis of rare disorders, and preemptive 
genotyping to guide medication prescribing at the point of care.4,6-9
Given the potential for such dramatic improvements in personal and public health, genomics 
deserves special consideration of how to successfully integrate advances into clinical care. 
Similar to the incorporation of most new technologies, clinical integration of genomic 
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medicine has been slow, even for applications with proven effectiveness.8,10 The lag has 
been attributed to multiple factors relevant to a variety of stakeholders, including limited 
evidence that genetic tests improve individual health outcomes and a lack of clinician 
education about genomic medicine. 4,8,10-12 The lack of evidence of efficacy in most 
genomic medicine applications has been a major challenge, leading to recommendations for 
alternatives to randomized controlled trials, new models of comparative effectiveness 
research, and emphasis on the importance of patient utility and the ability of patients to 
interpret genomic test results to make decisions, take action, or better understand themselves 
and their health.13-15 However, barriers for the conduct of such research have been largely 
unexplored.
Although inadequate physician understanding of genetics has been acknowledged for 
decades, leading to calls for more education,16-18 physicians still are generally reluctant to 
incoroporate genomics and genetic risk assessment into their clinical practice, and some lack 
confidence in their ability to relay results to their patients.19-22 Some are also skeptical of 
the impact genomic medicine would have on patient care and some require more 
professional education in order to better integrate it into standard patient care.19,22 Other 
barriers relate to concerns about the ethical, legal, and social implications of genetic testing 
and technologies, leading both patients and clinicians to be concerned about risks associated 
with their use.23
To gather data on optimal practices for successful and sustained integration of genomic 
medicine into practice, the NIH National Human Genome Research Institute (NHGRI) 
funded six genomic medicine demonstration projects aimed at: 1) linking existing genomic 
medicine efforts; 2) developing new collaborative projects in diverse settings and 
populations; 3) providing evidence to support the use of genomic information in clinical 
care; and 4) sharing best practices for genomic medicine implementation, diffusion, and 
sustainability.8,24 These clinical studies comprised the Implementing GeNomics In PracTicE 
(IGNITE) network, and employed diverse genomic medicine interventions (e.g., genetic 
testing for tailoring drug prescribing, including CYP2C19 genotyping for clopidogrel, 
APOL1 testing for risk for end stage kidney disease in African-Americans with 
hypertension; testing for monogenic diabetes; and evaluation of a family history tool for use 
by primary care providers) in a variety of clinical settings.24 These settings include primary 
care and community health clinics, inpatient units, and academic medical centers.
Much of the research on genomic medicine integration to date has focused on identifying 
and addressing barriers of single applications of genomic medicine at the level of the 
individuals directly involved with implementation, primarily patients and providers.8 Less 
attention has been paid to rigorously examining barriers to implementation from an 
organizational, systems-level perspective across a broad range of clinical practice settings. 
Additionally, understanding how genomic implementation affects a health system all the 
way from patients to hospital leadership requires further undersatnding. To address this gap, 
we conducted a formal qualitative study, using the Consolidated Framework for 
Implementation Research (CFIR),25 to identify system-level factors that have played a role 
in the implementation of genomic medicine applications represented by the IGNITE 
Network studies.
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Materials and Methods
Participants
We interviewed study team members from each of six IGNITE projects, including a 
principal Investigator and the project manager from each project. We asked the PI of each 
project to name two additional individuals from their project who could address barriers and 
facilitators to implementation. These individuals were typically coordinators or a study co-
investigator from one of their IGNITE project sites.
Instrument Development and Recruitment
The study team developed a semi-structured interview guide (see Appendix A), based upon 
the Consolidated Framework for Implementation Research (CFIR).25 The CFIR is one 
approach to understanding the success or failure of integration of any aspect of genomic 
medicine into clinical practice, and includes multiple constructs that allow one to analyze a 
variety of applications represented by the IGNITE Network, including those which may be 
multifactorial and representative of the patient, provider, organization, payer, and policy 
levels.25. While CFIR includes five domains: inner setting, outer setting, characteristics of 
the people involved, the intervention characteristics, and the implementation process, we 
chose to focus specifically on the domain of the inner setting based upon its relevance to our 
initial research question which was to identify system level factors affecting implementation 
of genomic research findings into the clinical setting. The broad range of practice settings in 
the IGNITE project provided important input that can be useful across different 
organizations (e.g., academic and non-academic) and different practice settings (e.g., 
specialty care and general practice, community-based and urban-based).
A study coordinator sent an email describing the study to potential interviewees and 
scheduled a telephone interview, regardless if projects were in the initiation or recruitment 
phase. The interviews followed the semi-structured interview guide (see Appendix A) which 
included questions asking interviewees to describe their study site(s), the progress at each 
site, and factors facilitating or impeding implementation of the project. Refinement of the 
interview guide was an iterative process: after the first three interviews, the questions were 
revised for clarity. Interviews were conducted by two of the investigators (BB and NS). We 
probed on responses to specifically ask about several organizational factors, including 1) 
infrastructure changes needed to accommodate the intervention; 2) stakeholder engagement; 
3) adequacy of resources to support the implementation; 4) level of organizational 
receptivity to the project; and 5) perceived need for their intervention.
All interviews were digitally recorded over the phone after obtaining verbal consent. The 
interviews lasted between 15 and 70 minutes, and were transcribed, de-identified and 
entered into QSR International’s NVivo 10.0 for coding and analysis.
Data Analysis
Study investigators met after reviewing a subset of transcripts to develop a coding system 
through an iterative process standard for content analysis.26 Initial codes related directly to 
the CFIR framework inner-setting as well as questions asked during the interviews (for 
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example: barriers to implementation, progress of the project at various sites, etc.). 
Subsequent codes were added that emerged through a close reading of the data. Three 
transcripts were coded by two investigators during the initial codebook development phase, 
with an additional eight transcripts independently coded by these investigators. Once the 
codebook was stabilized, all transcripts were double coded. Differences in coding were 
resolved by consensus to achieve 100% consistency. After all transcripts were coded, the 
investigators reviewed the coded data to identify dominant themes.26 We selected 
representative quotes to illustrate pertinent findings. The study protocol was classified as 
exempt by the Institutional Review Board of the University of Pennsylvania.
Results
Twenty persons associated with the IGNITE network participated in the open-ended semi-
structured interviews. These included six principal investigators, five project managers, and 
nine study coordinators. No network members refused participation.
Guided by the CFIR constructs, system and site-level barriers and facilitators to 
implementation of genomic medicine research and interventions, as well as clinical factors, 
were identified. Overall, a majority of those interviewed discussed patient and site 
characteristics including demographics, geographic location, size of clinic or hospital, and 
clinic setting (rural/urban, academic/community). These characteristics were often presented 
as both barriers and facilitators based on the stage of the project and whether studies were 
designed to recruit patients for genomic testing or clinicians for changes in practice. Stage of 
project implementation also varied among IGNITE project sites, with some interviews 
including discussion of implementation of the research project, while others focused on the 
implementation of genomic testing in clinical care. The CFIR inner-setting constructs 
identified across IGNITE projects, with examples for both research and overall genomic 
testing implementation, are presented below. Table 1 summarizes the study findings.
Barriers
Incorporating Genomics into Electronic Health Records—Limitations in 
technology, specifically integration of new genomic data and clinical decision support tools 
into electronic health records (EHR), were identified as barriers to implementation for both 
research and clinical genomic testing. Integration of test results and incorporation of clinical 
decision support tools were goals when considering changes to the EHR. Limitations within 
current medical record systems were mentioned in a number of interviews, and common 
concerns included the inability to automatically upload data elements, having to scan results 
into the EHR, and as one principal investigator discussed:
Their electronic health record actually does not have … the… functionality that 
allows them to do interruptive clinical decision support… (PI).
Interviewees also mentioned that making technological advancements within hospitals and 
clinics was crucial for implementing genetic and genomic testing into everyday practice. As 
one principal investigator pointed out:
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…incorporation of computer logic at the point of care is going to be the only way 
that genomics can work. And consequently – right now, if you look at the major 
vendors…they don’t have a lot in the way of genomics incorporated (PI).
This PI stressed the fact that implementation of genomic testing would require EHR vendors 
to update their systems and incorporate the necessary technologies to facilitate testing.
Reluctance to Participate in Genomics Studies—Participants described a culture of 
physician reluctance to participate in genomic focused clinical studies due to unfamiliarity 
with genomic testing or ambiguity in the interpretation and application of its results. This 
reluctance stemmed from clinician difficulty in envisioning how implementation of genetic 
testing would improve patient health or a low comfort level in discussing results if 
implications were unknown. One principal investigator mentioned the lack of buy-in from 
clinicians without a guarantee of benefit for patients:
… there wasn’t real research buy-in. I think this is a research naïve site. And they 
said, well, is it definitely going to help our patients? And we said no, because with 
research you never know if it will definitely help your patients. And they said, well, 
if it’s not definitely going to help our patients, were not going to do it. (PI)
Along with physician concerns, patient support was also perceived to be lacking, which 
negatively affected the study recruitment process. Difficulties with both patient and 
physician recruitment was expressed by a principal investigator who mentioned how the idea 
of doing research studies in a clinical setting resulted in reduced participation:
The biggest thing I think is often the barrier can be that you say the word 
“research” – and the community engagement person said this, too – and you can 
scare people off. And so, getting people to understand that this is research in the 
enhancement of clinical care. (PI)
Participants linked physician and patient concerns about being involved in clinical studies 
with difficulty in implementing genomic testing in practice.
Uncertain Reimbursement for Clinical Programs—Some interviewees felt that the 
testing for genomic markers could not be implemented into clinical practice due to the 
uncertainty of reimbursement outside of a research study. One principal investigator noted 
that, although hospital administration was supportive of research, obstacles in a non-research 
setting would be higher due to the cost of the test:
The big thing is the reimbursement. I mean, we approached them and they were 
extraordinarily receptive and helpful. But we made it clear that this was a research 
study and that the cost would not be relayed to the patient, would not be relayed to 
the health system…I think the obstacles in a non-research setting would be much 
higher if these are costly tests and not being reimbursed by the payers. (PI)
Facilitators
Investigator and Clinician Communication—The majority of those interviewed 
discussed that good communication among sites of an IGNITE project and within individual 
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projects were facilitators to implementation of the studies. With respect to the former, 
various forms of communication, including webinars, conference calls, and presentations, 
were used to solicit feedback and unify study sites. Collaborative strategies were helpful for 
the majority of those who mentioned them, with one principal investigator commenting:
It’s just a reminder of how great teamwork is when it works, because I couldn’t 
have any idea. What can you do in EPIC and what can you do with the interface? 
And then you have all these different people who know. (PI)
This same principal investigator also mentioned how monthly meetings among sites within 
an IGNITE project allowed for the opportunity to discuss problems and provide feedback:
Yeah, very helpful. We basically – the format is basically we start with the progress 
of the study, and then we bring up just different kinds of issues that affect all of 
us…But it’s just kind of nice to have one meeting a month where people can just 
sort of talk about things that are concerning. (PI)
Communication among projects was necessary for successful implementation of each 
research study and for consistency in implementation, but internal communication within a 
given site was noted as being critical to continued success both throughout the study period 
and during the transition from research into clinical practice. Interviewees described that 
regular feedback from clinicians about genomic testing integration into current practice was 
important. One study coordinator noted that feedback allowed staff to modify their 
approach, if necessary, to get physicians involved or patients recruited into research studies. 
One principal investigator stressed the importance of communication among stakeholders as 
essential for long-term success:
And they have so much to do and so many different things to deal with that they 
just maybe don’t want to think about something that’s new and seems 
challenging…And so I think what is going to be interesting over probably the next 
year as that program matures is that – my guess is that that’s going to rub off – 
right? He’s going to talk to his colleagues and say this is really helpful…But I think 
we can already project that as physicians feel like it’s helpful in clinical practice, 
they’re going to share that with their colleagues. (PI)
A project manager also mentioned that physician feedback allowed for better gauging of 
overall interest and engagement in the project:
We have a lot of clinicians here that are engaged in the project. So we’re getting 
feedback about that. So it shows me that there is an interest and curiosity at trying 
to get more engaged in the protocol and understand that. (Project Manager)
Clinical Leadership as Facilitators of Genomic Implementation—Similar to 
internal communication, clinician enthusiasm, support, and championing genomic testing 
throughout the study period and into clinical practice was mentioned by all sites as a 
facilitator for implementation. This included backing by physician leaders and early 
adopters. Without this encouragement, studies at individual sites would find it extremely 
challenging to implement genomic testing. One principal investigator discussed physicians 
who were early adopters and the benefit of early interest in moving the study forward:
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… trying to figure out where people are on the spectrum – where the clinicians are 
on that spectrum, I think is important to helping move them along. Because if their 
inclination is to be generally an early adopter or for whatever reason they’re 
interested specifically in this and willing to be an early adopter, then it’s just an 
easier conversation than if somebody views this as just another thing that’s going to 
complicate their practice and take more time that they don’t have. (PI)
Hospital Leadership Engagement Throughout Programming—Along with 
physician guidance facilitating the implementation, many interviewees also mentioned high-
level hospital leadership engagement as important to study initiation and long-term success. 
The same principal investigator who discussed the importance of physicians also commented 
on how leadership made their project a priority:
I think we had high level support in the right places…So I think the fact that our 
chief information officer totally bought into this, and basically – especially early on 
pushed some of our things to the front of the line, made them a high priority with 
her team. I think that that really helped. (PI)
Another principal investigator commented on how engagement from hospital leadership 
helped with funding:
[the site] took on our – the IT aim … because the Chief Medical Officer, and the 
Chief Information Officer both knew about [the program] and were incredibly 
supportive about what it was doing. So they decided that they would take on the 
integration with the IT system themselves without any additional funding. (PI)
The general consensus was that the long-term success of genomic testing in the clinical 
realm required the support of hospital leadership, with one project manager echoing this 
view:
Basically, I think it comes down to a lot of discussions at the institutional level to 
get the concept approved, where you’re talking to the CMO or the Chief Medical 
Officer in the hospital to prove that or to show that there is value…And then from 
there it just helps grease the wheels in actually making it happen with some of the 
clinics. (Project Manager)
Discussion
Until now, there had been limited examination of the barriers and facilitators to 
implementation of genomic medicine in clinical practice, particularly from an organizational 
and systems-level perspective.8,27,28 While Manolio et al. provided a summary of potential 
challenges to genomic implementation,8 this study, as a next step, now directly addresses 
some of these potential challenges by conducting qualitative interviews, guided by the CFIR 
framework,25 with research professionals on a wide-range of clinical topics. Several CFIR 
inner-setting constructs emerged as being consistent and important across IGNITE projects, 
with distinct differences between facilitators and barriers to implementation. Slow 
technological advancement and EHR integration, skepticism and reluctance towards genetic 
medicine from physicians, as well as slow recruitment of patients, were barriers to 
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implementation mentioned across IGNITE projects. Our findings build on prior work by 
Gottesman et al., that showed how EHRs can help facilitate the implementation of genomic 
medicine into practice, emphasizing the need for more rapid EHR integration.29 This initial 
integration of genomic medicine into EHRs may provide a path to easier implementation of 
testing by physicians. Additionally, lack of reimbursement for genetic medicine was 
mentioned as a major barrier to implementation in a clinical setting with both physicians and 
leadership voicing concern about reimbursement from insurance companies.
Communication among a variety of stakeholders within and between IGNITE projects, 
including feedback on successes and failures, were important facilitators and keys to 
success. This communication and feedback was seen as critical to engagement and buy-in by 
physicians and hospital management, and particularly useful for both implementation of 
initial genomic research studies and eventually for clinicians to incorporate genetic medicine 
into usual care. A lack of physician buy-in has also been shown in other studies to be a 
barrier to implementation, and overcoming this barrier is an eventual necessity in order to 
achieve successful implementation.10,11,30 In a study by Hamilton et al., physicians did not 
view genetic services as being advantageous or necessary for patient care; however, those 
physicians who were already versed and interested in genetic medicine were also more 
likely to implement it.30 Similar findings were echoed throughout the IGNITE study with 
interviewees expressing that clinicians seemed uncertain as to how genetic medicine would 
help their patients or provide benefit beyond current practice standards.
Finally, patient recruitment into genomic testing studies, as a first step towards 
demonstrating the utility of genetic testing in practice, was shown to be an important barrier 
to ultimate implementation. Access to patients, as well as logistical challenges of working 
within the constraints of clinic visits, was challenging at many of the IGNITE sites. This 
further explores the importance of incorporating patients into the testing process as 
described by IGNITE network.12 These difficulties with patient recruitment, together with 
the fact that physicians want evidence before they implement a new intervention, highlights 
the importance of identifying solutions to improving clinical study implementation.
While barriers such as technological advancements and reimbursement may not be readily 
solved, physician buy-in may be addressed with increased information about genomic 
testing early in medical training. Our findings suggest that this education may then benefit 
from continued open communication and feedback between researchers, clinicians, and 
administrators. Nonetheless, even with increased education, technological and financial 
barriers will remain important obstacles to implementing genomics in practice. These needs, 
along with increasing patient participation in genetic and genomic testing, require further 
exploration.
There were several limitations in this study. First, only research faculty and staff involved 
with the IGNITE projects were interviewed. Thus, no clinicians, staff, or hospital 
administration perspectives were provided on implementation, although they communicated 
their viewpoints with interviewees. Getting information indirectly from these individuals 
may result in differences in opinions expressed about implementation between those 
interviewed and those who work on the front lines in the clinics. This may be particularly 
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important given that many of the views shared by interviewees describe feelings about 
stakeholder participation or reluctance, and reasons for these may differ if clinicians, 
patients, or hospital leadership were interviewed themselves. Additionally, many of the 
interviews were conducted while project sites were still in the project initiation or 
recruitment phase, which may have limited the topics of conversation to recruitment 
challenges for research instead of discussion about implementation of genomic medicine on 
a broader scale. While these early phases on implementation are important to understand, 
interviews at later stages of project implementation may garner different information. 
Finally, a widespread group of sites within each of the IGNITE projects were discussed by 
interviewees. While this allowed for a robust discussion of different challenges and best-
practices, the barriers may be specific to both research and to an individual site.
Overall, this study provides important information about barriers and facilitators to studying 
and implementing genomic medicine. Efforts in the future might be directed towards 
incorporating genetic information and results into hospital EHR, as well as research to 
determine if reimbursement is warranted for genomic medicine or alternative methods for 
incorporation of testing if reimbursement is not feasible. It may be crucial to address these 
challenges before widespread implementation can be accomplished. Future research in the 
area of genomic medicine implementation can expand on these findings by incorporating the 
perspective of additional stakeholders including patients, administrators, and clinicians.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
We thank Selena Suhail-Sindhu, recent graduate of the public health program at Columbia University, for her 
assistance with data collection and management, and Kara Silberthau, medical student at the University of 
Pennsylvania, for her contribution to data management and analysis.
Conflicts of Interest and Disclosures
Support for this study was provided from the Implementation Science Working Group at the University of 
Pennsylvania and the NHGRI U01-HG007266. Additional IGNITE Network grants include: U01-HG007269, U01-
HG007253, U01-HG007762, U01-HG007282, U01-HG007775, U01-HG007278.
References
1. Collins FS, McKusick VA. Implications of the Human Genome Project for medical science. JAMA. 
2001;285(5):540–544. [PubMed: 11176855] 
2. Subramanian G, Adams MD, Venter JC, Broder S. Implications of the human genome for 
understanding human biology and medicine. JAMA. 2001;286(18):2296–2307. [PubMed: 
11710896] 
3. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795. 
[PubMed: 25635347] 
4. McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and 
opportunities. Sci Transl Med. 2013;5(189):189sr184.
5. Green ED, Guyer MS, National Human Genome Research I. Charting a course for genomic 
medicine from base pairs to bedside. Nature. 2011;470(7333):204–213. [PubMed: 21307933] 
Zebrowski et al. Page 10
Genet Med. Author manuscript; available in PMC 2019 May 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
6. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl 
Res. 2009;154(6):277–287. [PubMed: 19931193] 
7. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. 
[PubMed: 26469045] 
8. Manolio TA, Chisholm RL, Ozenberger B, et al. Implementing genomic medicine in the clinic: the 
future is here. Genet Med. 2013;15(4):258–267. [PubMed: 23306799] 
9. Hofman V, Ilie M, Long E, et al. Detection of circulating tumor cells from lung cancer patients in 
the era of targeted therapy: promises, drawbacks and pitfalls. Curr Mol Med. 2014;14(4):440–456. 
[PubMed: 24730524] 
10. Burke W, Korngiebel DM. Closing the gap between knowledge and clinical application: challenges 
for genomic translation. PLoS Genet. 2015;11(2):e1004978. [PubMed: 25719903] 
11. Williams MS. Genomic medicine implementation: learning by example. Am J Med Genet C Semin 
Med Genet. 2014;166C(1):8–14. [PubMed: 24616394] 
12. Sperber NR, Carpenter JS, Cavallari LH, et al. Challenges and strategies for implementing 
genomic services in diverse settings: experiences from the Implementing GeNomics In pracTicE 
(IGNITE) network. BMC Med Genomics. 2017;10(1):35. [PubMed: 28532511] 
13. Grosse SD, McBride CM, Evans JP, Khoury MJ. Personal utility and genomic information: look 
before you leap. Genet Med. 2009;11(8):575–576. [PubMed: 19623080] 
14. Bunnik EM, Janssens AC, Schermer MH. Personal utility in genomic testing: is there such a thing? 
J Med Ethics. 2015;41(4):322–326. [PubMed: 24872596] 
15. Botkin JR, Teutsch SM, Kaye CI, et al. Outcomes of interest in evidence-based evaluations of 
genetic tests. Genet Med. 2010;12(4):228–235. [PubMed: 20118789] 
16. Hofman KJ, Tambor ES, Chase GA, Geller G, Faden RR, Holtzman NA. Physicians’ knowledge of 
genetics and genetic tests. Acad Med. 1993;68(8):625–632. [PubMed: 8352875] 
17. Hayflick SJ, Eiff MP. Role of primary care providers in the delivery of genetics services. 
Community Genet. 1998;1(1):18–22. [PubMed: 15178983] 
18. Suther S, Goodson P. Barriers to the provision of genetic services by primary care physicians: a 
systematic review of the literature. Genet Med. 2003;5(2):70–76. [PubMed: 12644775] 
19. Weipert CM, Ryan KA, Everett JN, et al. Physician Experiences and Understanding of Genomic 
Sequencing in Oncology. J Genet Couns. 2017.
20. Vassy JL, Green RC, Lehmann LS. Genomic medicine in primary care: barriers and assets. 
Postgrad Med J. 2013;89(1057):615–616. [PubMed: 24129030] 
21. Mikat-Stevens NA, Larson IA, Tarini BA. Primary-care providers’ perceived barriers to integration 
of genetics services: a systematic review of the literature. Genet Med. 2015;17(3):169–176. 
[PubMed: 25210938] 
22. Chow-White P, Ha D, Laskin J. Knowledge, attitudes, and values among physicians working with 
clinical genomics: a survey of medical oncologists. Hum Resour Health. 2017;15(1):42. [PubMed: 
28655303] 
23. Hazin R, Brothers KB, Malin BA, et al. Ethical, legal, and social implications of incorporating 
genomic information into electronic health records. Genet Med. 2013;15(10):810–816. [PubMed: 
24030434] 
24. Weitzel KW, Alexander M, Bernhardt BA, et al. The IGNITE network: a model for genomic 
medicine implementation and research. BMC Med Genomics. 2016;9:1. [PubMed: 26729011] 
25. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering 
implementation of health services research findings into practice: a consolidated framework for 
advancing implementation science. Implement Sci. 2009;4:50. [PubMed: 19664226] 
26. Huberman AM, Miles MB. Understanding and Validity in Qualitative Research In: Huberman AM, 
Miles MB, eds. The Qualitative Researcher’s Companion. Thousand Oaks, CA: SAGE 
Publications, Inc.; 2002:36–65.
27. Luzum JA, Pakyz RE, Elsey AR, et al. The Pharmacogenomics Research Network Translational 
Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across 
Diverse Healthcare Systems. Clin Pharmacol Ther. 2017;102(3):502–510. [PubMed: 28090649] 
Zebrowski et al. Page 11
Genet Med. Author manuscript; available in PMC 2019 May 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
28. Shuldiner AR, Relling MV, Peterson JF, et al. The Pharmacogenomics Research Network 
Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. 
Clin Pharmacol Ther. 2013;94(2):207–210. [PubMed: 23588301] 
29. Gottesman O, Kuivaniemi H, Tromp G, et al. The Electronic Medical Records and Genomics 
(eMERGE) Network: past, present, and future. Genet Med. 2013;15(10):761–771. [PubMed: 
23743551] 
30. Hamilton AB, Oishi S, Yano EM, Gammage CE, Marshall NJ, Scheuner MT. Factors influencing 
organizational adoption and implementation of clinical genetic services. Genet Med. 2014;16(3):
238–245. [PubMed: 23949572] 
Zebrowski et al. Page 12
Genet Med. Author manuscript; available in PMC 2019 May 24.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Zebrowski et al. Page 13
Ta
bl
e 
1.
B
ar
rie
rs
 a
nd
 F
ac
ili
ta
to
rs
 to
 G
en
om
ic
 T
es
tin
g 
Im
pl
em
en
ta
tio
n 
ba
se
d 
on
 th
e 
CF
IR
 F
ra
m
ew
o
rk
 In
ne
r S
et
tin
g 
Co
ns
tru
ct
s2
5
C
FI
R
 F
ra
m
ew
o
rk
 –
 In
ne
r 
Se
tti
ng
A
pp
lie
d 
C
on
st
ru
ct
C
FI
R
 C
on
st
ru
ct
Im
pl
em
en
ta
tio
n 
A
pp
lic
at
io
n 
fo
r 
R
es
ea
rc
h 
an
d 
C
lin
ic
al
 P
ra
ct
ic
e
Ba
rr
ie
rs
In
co
rp
or
at
in
g 
ge
no
m
ic
s i
nt
o 
el
ec
tro
ni
c 
he
al
th
 
re
co
rd
s
Av
ai
la
bl
e 
Re
so
ur
ce
s
St
ak
eh
ol
de
r E
ng
ag
em
en
t
•
 
La
ck
 o
f i
nt
eg
ra
tio
n 
of
 d
ec
isi
on
 su
pp
or
t t
oo
ls 
or
 te
sti
ng
 re
su
lts
 in
to
 e
le
ct
ro
ni
c 
he
al
th
 re
co
rd
s (
EH
R)
•
 
Cu
rre
nt
 te
ch
no
lo
gy
 la
ck
s a
pp
ro
pr
ia
te
 c
om
pu
te
r l
og
ic
 fo
r i
nt
er
pr
et
at
io
n 
of
 g
en
om
ic
 te
sti
ng
•
 
R
eq
ui
re
d 
IT
 c
ol
la
bo
ra
tio
n 
fo
r i
nt
eg
ra
tio
n
R
el
uc
ta
nc
e 
to
 d
o 
ge
no
m
ic
s r
es
ea
rc
h
Cu
ltu
re
St
ak
eh
ol
de
r E
ng
ag
em
en
t
•
 
U
ne
as
e 
in
 a
cc
ep
tin
g 
re
se
ar
ch
 w
ith
ou
t g
ua
ra
nt
ee
 fo
r i
m
pr
ov
em
en
t o
f p
at
ie
nt
 h
ea
lth
•
 
Ph
ys
ic
ia
n 
pr
ef
er
en
ce
 fo
r k
no
w
n
 te
ch
no
lo
gy
 o
r p
ro
ce
du
re
s
•
 
N
ot
 a
ll 
pa
tie
nt
s h
av
e 
co
m
fo
rt 
w
ith
 g
en
om
ic
 te
sti
ng
 a
nd
 li
m
ite
d 
pa
tie
nt
 b
u
y-
in
R
ei
m
bu
rs
em
en
t
In
fra
str
uc
tu
re
 C
ha
ng
es
•
 
La
ck
 o
f f
un
di
ng
 fo
r t
es
tin
g 
ou
tsi
de
 o
f r
es
ea
rc
h 
se
tti
ng
•
 
Li
m
ite
d 
av
en
u
es
 fo
r r
ei
m
bu
rs
em
en
t f
or
 g
en
om
ic
 te
sti
ng
 in
 c
ur
re
nt
 h
ea
lth
ca
re
 c
lim
at
e
Fa
ci
lit
at
or
s
In
v
es
tig
at
or
 a
nd
 C
lin
ic
ia
n 
co
m
m
un
ic
at
io
n
N
et
w
o
rk
s &
 C
om
m
un
ic
at
io
n
G
oa
ls 
&
 F
ee
db
ac
k
•
 
U
se
 o
f v
ar
io
us
 p
la
tfo
rm
s t
o 
sh
ar
e 
in
fo
rm
at
io
n 
ab
ou
t r
es
ea
rc
h 
pr
oje
cts
: m
eet
ing
s, c
on
fer
en
ces
, a
nd
 gr
an
d r
ou
nd
s
•
 
Co
nf
er
en
ce
 c
al
ls 
fo
r a
ll 
sit
es
 to
 in
tro
du
ce
 st
ud
y, 
st
an
da
rd
iz
e 
pr
oc
ed
ur
es
, a
nd
 p
ro
bl
em
 so
lv
e
•
 
So
lic
ita
tio
n 
of
 fe
ed
ba
ck
 in
 d
et
ai
lin
g 
be
st 
pr
ac
tic
es
 fo
r p
ro
jec
t im
ple
me
nta
tio
n
•
 
Co
m
m
un
ic
at
io
n 
be
tw
ee
n 
cl
in
ic
ia
ns
 a
bo
ut
 g
en
om
ic
 te
sti
ng
 a
nd
 in
te
gr
at
in
g 
ge
no
m
ic
 te
sti
ng
 in
to
 p
ra
ct
ic
e
Cl
in
ic
ia
n 
ch
am
pi
on
s a
s f
ac
ili
ta
to
rs
 o
f g
en
om
ic
 
im
pl
em
en
ta
tio
n
St
ak
eh
ol
de
r E
ng
ag
em
en
t
Le
ad
er
sh
ip
 E
ng
ag
em
en
t
•
 
Es
ta
bl
ish
m
en
t o
f p
hy
sic
ia
n 
le
ad
er
sh
ip
 o
n 
a 
de
pa
rtm
en
ta
l l
ev
el
 to
 a
ss
ist
 w
ith
 re
cr
ui
tm
en
t a
nd
 b
u
y-
in
•
 
U
se
 o
f e
ar
ly
 a
do
pt
er
s t
o 
en
co
ur
ag
e 
pa
rti
ci
pa
tio
n 
fro
m
 o
th
er
 c
lin
ic
ia
ns
•
 
R
ec
om
m
en
da
tio
n 
to
 u
se
 te
sti
ng
 a
nd
 su
pp
or
t t
oo
ls 
be
tw
ee
n 
cl
in
ic
ia
ns
Le
ad
er
sh
ip
 e
ng
ag
em
en
t
Le
ad
er
sh
ip
 E
ng
ag
em
en
t
Av
ai
la
bl
e 
Re
so
ur
ce
s
•
 
H
os
pi
ta
l a
dm
in
ist
ra
tio
n 
or
 le
ad
er
sh
ip
 su
pp
or
t f
or
 re
se
ar
ch
 a
nd
 re
qu
ire
d 
re
so
ur
ce
s
•
 
A
cc
es
s t
o 
fu
nd
in
g 
or
 a
dm
in
ist
ra
tiv
e 
as
se
ts
 fo
r r
es
ea
rc
h 
re
qu
ire
d 
ch
an
ge
s t
o 
te
ch
no
lo
gy
,
 
la
bs
, o
r c
lin
ic
 se
tti
ng
s
•
 
B
uy
-in
 fr
om
 C
-le
v
el
 to
 in
cr
ea
se
 p
ro
jec
t p
rio
rity
 an
d r
ed
uc
e a
dm
ini
str
ati
v
e 
co
n
ce
rn
s
Genet Med. Author manuscript; available in PMC 2019 May 24.
